Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Meda Pharmaceuticals

Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU
Telephone: 0845 460 0000
Fax: 0845 460 0002
Medical Information Direct Line: +44 (0)1748 828 810
Medical Information e-mail: meda@professionalinformation.co.uk
Medical Information Fax: +44 (0)1748 828 801
Out of Hours contact: +44 (0)1748 828 810

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 24/06/2010
SPC Aldara 5% Cream

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 24/06/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Updated on 19/10/2009 and displayed until 24/06/2010
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 17/02/2009 and displayed until 19/10/2009
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 7 - Marketing Authorisation Holder
Updated on 30/04/2007 and displayed until 17/02/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 27/02/2007 and displayed until 30/04/2007
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
Updated on 06/09/2006 and displayed until 27/02/2007
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 22/08/2006 and displayed until 06/09/2006
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 10/05/2006 and displayed until 22/08/2006
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
Updated on 04/08/2004 and displayed until 10/05/2006
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
Updated on 29/03/2004 and displayed until 04/08/2004
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 26/09/2003 and displayed until 29/03/2004
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 04/08/2003 and displayed until 26/09/2003
Reasons for adding or updating:
  • Removal of Black Triangle
Updated on 19/02/2002 and displayed until 04/08/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 22/01/2002 and displayed until 19/02/2002
Reasons for adding or updating:
  • Addition of Black Triangle
Updated on 07/01/2002 and displayed until 22/01/2002
Reasons for adding or updating:
  • Addition of Black Triangle
Updated on 18/12/2001 and displayed until 07/01/2002
Reasons for adding or updating:
  • Addition of Black Triangle
Updated on 03/12/2001 and displayed until 18/12/2001
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.3 - Preclinical Safety Data
Updated on 09/07/2001 and displayed until 03/12/2001
Reasons for adding or updating:
  • Addition of Black Triangle
Updated on 06/09/1999 and displayed until 09/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  imiquimod